GLP-1 medications like Ozempic and Wegovy have exploded in popularity for diabetes treatment and weight loss, but their rapid rise is creating new considerations for anesthesia providers. As more patients arrive for procedures while taking these medications, CRNAs and anesthesia teams must navigate evolving guidelines, potential aspiration risks, and uncertainty about perioperative management. In this episode, Amy Reed, Ph.D, CRNA returns to discuss the latest research and recommendations surrounding GLP-1 receptor agonists in anesthesia practice. Here’s some of what you’ll hear in this episode: 💊 GLP-1 medications aren’t new but their popularity is ⚠️ Aspiration risk is still the primary anesthesia concern 📋 Guidelines are evolving and sometimes conflicting 🔍 Point-of-care gastric ultrasound is gaining traction 📊 More research is still needed Visit us online: https://beyondthemaskpodcast.com/ The 1099 CRNA Institute: https://aana.com/1099 Get the CE Certificate here (and directly submit to the NBCRNA): https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246 Now you can watch the show on YouTube! Check it out here: https://www.youtube.com/channel/UCknrmkRxiwtYk7LUjSV6wmw?sub_confirmation=1

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related